Targeted therapies in gynecologic cancers

Current Cancer Drug Targets

Volumn 6, Issue 4, 2006, Pages 333-363

  Hye, Sook Chon ^a   Hu, Wei ^a   Kavanagh, John J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anticancer drugs; Cervical cancer; Clinical trials; Endometrial cancer; Ovarian cancer; Targeted therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADVEXIN; ANASTROZOLE; BEVACIZUMAB; CANERTINIB; CANFOSFAMIDE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FARNESYL TRANS TRANSFERASE; GEFITINIB; HISTONE DEACETYLASE; IMATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; NAVELBINE; OREGOVOMAB; OXALIPLATIN; PACLITAXEL; PERTUZUMAB; PROTEASOME; PROTEIN P53; RAF PROTEIN; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VATALANIB;

APOPTOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG TARGETING; ENDOMETRIUM CANCER; GASTROINTESTINAL STROMAL TUMOR; GYNECOLOGIC CANCER; HUMAN; MITOSIS; NONHUMAN; OVARY CANCER; REVIEW; UTERINE CERVIX CANCER;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE TRANSFER TECHNIQUES; GENITAL NEOPLASMS, FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; THALIDOMIDE; THIONUCLEOTIDES;

EID: 33745491825     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800906777441799     Document Type: Review

References (226)

1. Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R. C.; Ghafoor, A.; Feuer, E. J.; Thun, M. J. Cancer statistics, 2005. CA. Cancer J. Clin. 2005, 55, 10-30.
2. Harries, M.; Kaye, S. B. Recent advances in the treatment of epithelial ovarian cancer. Exp. Opin. Investig. Drugs 2001, 10, 1715-1724.
3. Waggoner, S. E. Cervical cancer. Lancet 2003, 361, 2217-2225.
4. Elit, L.; Hirte, H. Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Curr. Opin. Obstet. Gynecol. 2002, 14, 67-73.
5. Korsmeyer, S. J.; Wei, M. C.; Saito, M.; Weiler, S.; Oh, K. J.; Schlesinger, P. H. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000, 7, 1166-1173.
6. Sun, X. M.; MacFarlane, M.; Zhuang, J.; Wolf, B. B.; Green, D. R.; Cohen, G. M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem. 1999, 274, 5053-5060.
7. Yang, Y. L.; Li, X. M. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res. 2000, 10, 169-177.
8. Kim, R.; Tanabe, K.; Uchida, Y.; Emi, M.; Inoue, H.; Toge, T. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother. Pharmacol. 2002, 50, 343-352.
9. Li, P.; Nijhawan, D.; Budihardjo, I.; Srinivasula, S. M.; Ahmad, M.; Alnemri, E. S.; Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91, 479-489.
10. Miyashita, T.; Krajewski, S.; Krajewska, M.; Wang, H. G.; Lin, H. K.; Liebermann, D. A.; Hoffman, B.; Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994, 9, 1799-1805.
11. Henry, H.; Thomas, A.; Shen, Y.; White, E. Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene 2002, 21, 748-760.
12. Trepel, M.; Groscurth, P.; Malipiero, U.; Gulbins, E.; Dichgans, J.; Weller, M. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer. J. Neurooncol. 1998, 39, 19-32.
13. Hussein, M. R.; Haemel, A. K.; Wood, G. S. Apoptosis and melanoma: molecular mechanisms. J. Pathol. 2003, 199, 275-288.
14. Smith, N. D.; Rubenstein, J. N.; Eggener, S. E.; Kozlowski, J. M. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J. Urol. 2003, 169, 1219-1228.
15. Baekelandt, M.; Kristensen, G. B.; Nesland, J. M.; Trope, C. G.; Holm, R. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J. Clin. Oncol. 1999, 17, 2061.
16. Tolcher, A. W. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin. Oncol. 2001, 28, 67-70.
17. Leung, S.; Miyake, H.; Zellweger, T.; Tolcher, A.; Gleave, M. E. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int. J. Cancer 2001, 91, 846-850.
18. Aguirre, D.; Boya, P.; Bellet, D.; Faivre, S.; Troalen, F.; Benard, J.; Saulnier, P.; Hopkins-Donaldson, S.; Zangemeister-Wittke, U.; Kroemer, G.; Raymond, E. Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 2004, 9, 797-805.
19. Frankel, A.; Buckman, R.; Kerbel, R. S. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res. 1997, 57, 2388-2393.
20. Kern, S. E.; Kinzler, K. W.; Bruskin, A.; Jarosz, D.; Friedman, P.; Prives, C.; Vogelstein, B. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991, 252, 1708-1711.
21. Santoso, J. T.; Tang, D. C.; Lane, S. B.; Hung, J.; Reed, D. J.; Muller, C. Y.; Carbone, D. P.; Lucci, J. A., 3rd; Miller, D. S.; Mathis, J. M. Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol. Oncol. 1995, 59, 171-178.
22. Kohler, M. F.; Berchuck, A.; Davidoff, A. M.; Humphrey, P. A.; Dodge, R. K.; Iglehart, J. D.; Soper, J. T.; Clarke-Pearson, D. L.; Bast, R. C., Jr.; Marks, J. R. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 1992, 52, 1622-1627.
23. Fujiwara, T.; Grimm, E. A.; Mukhopadhyay, T.; Cai, D. W.; Owen-Schaub, L. B.; Roth, J. A. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res. 1993, 53, 4129-4133.
24. Lang, F. F.; Bruner, J. M.; Fuller, G. N.; Aldape, K.; Prados, M. D.; Chang, S.; Berger, M. S.; McDermott, M. W.; Kunwar, S. M.; Junck, L. R.; Chandler, W.; Zwiebel, J. A.; Kaplan, R. S.; Yung, W. K. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. 2003, 21, 2508-2518.
25. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy - Introgen, RPR/INGN 201. Bio. Drugs 2003, 17, 216-222.
26. Zeimet, A. G.; Marth, C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 2003, 4, 415-422.
27. Wolf, J. K.; Bodurka, D. C.; Gano, J. B.; Deavers, M.; Ramondetta, L.; Ramirez, P. T.; Levenback, C.; Gershenson, D. M. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol. Oncol. 2004, 94, 442-448.
28. Constantinou, A. I.; Husband, A. Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4- hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex. Anticancer Res. 2002, 22, 2581-2585.
29. Kamsteeg, M.; Rutherford, T.; Sapi, E.; Hanczaruk, B.; Shahabi, S.; Flick, M.; Brown, D.; Mor, G. Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003, 22, 2611-2620.
30. Sapi, E.; Alvero, A. B.; Chen, W.; O'Malley, D.; Hao, X. Y.; Dwipoyono, B.; Garg, M.; Kamsteeg, M.; Rutherford, T.; Mor, G. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol. Res. 2004, 14, 567-578.
31. Yarden, Y.; Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2001, 2, 127-137.
32. Adjei, A. A. Ras signaling pathway proteins as therapeutic targets. Curr. Pharm. Des. 2001, 7, 1581-1594.
33. Teneriello, M. G.; Ebina, M.; Linnoila, R. I.; Henry, M.; Nash, J. D.; Park, R. C.; Birrer, M. J. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 1993, 53, 3103-3108.
34. Fabjani, G.; Kriegshaeuser, G.; Schuetz, A.; Prix, L.; Zeillinger, R. Biochip for K-ras Mutation Screening in Ovarian Cancer. Clin. Chem. 2005, 51, 784-787.
35. Niederacher, D.; An, H. X.; Cho, Y. J.; Hantschmann, P.; Bender, H. G.; Beckmann, M. W. Mutations and amplification of oncogenes in endometrial cancer. Oncology 1999, 56, 59-65.
36. Enomoto, T.; Inoue, M.; Perantoni, A. O.; Terakawa, N.; Tanizawa, O.; Rice, J. M. K-ras activation in neoplasms of the human female reproductive tract. Cancer Res. 1990, 50, 6139-6145.
37. Mammas, I. N.; Zafiropoulos, A.; Koumantakis, E.; Sifakis, S.; Spandidos, D. A. Transcriptional activation of H- and N-ras oncogenes in human cervical cancer. Gynecol. Oncol. 2004, 92, 941-948.
38. Johnston, S. R. Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer. Lancet Oncol. 2001, 2, 18-26.
39. Zimmerman, T. M.; Harlin, H.; Odenike, O. M.; Berk, S.; Sprague, E.; Karrison, T.; Stock, W.; Larson, R. A.; Ratain, M. J.; Gajewski, T. F. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J. Clin. Oncol. 2004, 22, 4816-4822.
40. Karp, J. E.; Lancet, J. E.; Kaufmann, S. H.; End, D. W.; Wright, J. J.; Bol, K.; Horak, I.; Tidwell, M. L.; Liesveld, J.; Kottke, T. J.; Ange, D.; Buddharaju, L.; Gojo, I.; Highsmith, W. E.; Belly, R. T.; Hohl, R. J.; Rybak, M. E.; Thibault, A.; Rosenblatt, J. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001, 97, 3361-3369.
41. Rao, S.; Cunningham, D.; de Gramont, A.; Scheithauer, W.; Smakal, M.; Humblet, Y.; Kourteva, G.; Iveson, T.; Andre, T.; Dostalova, J.; Illes, A.; Belly, R.; Perez-Ruixo, J. J.; Park, Y. C.; Palmer, P. A. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 2004, 22, 3950-3957.
42. Lyons, J. F.; Wilhelm, S.; Hibner, B.; Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 2001, 8, 219-225.
43. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64, 7099-7109.
44. Strumberg, D.; Richly, H.; Hilger, R. A.; Schleucher, N.; Korfee, S.; Tewes, M.; Faghih, M.; Brendel, E.; Voliotis, D.; Haase, C. G.; Schwartz, B.; Awada, A.; Voigtmann, R.; Scheulen, M. E.; Seeber, S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 2005, 23, 965-972.
45. Nielsen, J. S.; Jakobsen, E.; Holund, B.; Bertelsen, K.; Jakobsen, A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int. J. Gynecol. Cancer 2004, 14, 1086-1096.
46. Bookman, M. A.; Darcy, K. M.; Clarke-Pearson, D.; Boothby, R. A.; Horowitz, I. R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 2003, 21, 283-290.
47. Sato, S.; Ito, K.; Ozawa, N.; Yajima, A.; Sasano, H. Expression of c-myc, epidermal growth factor receptor and c-erbB-2 in human endometrial carcinoma and cervical adenocarcinoma. Tohoku J. Exp. Med. 1991, 165, 137-145.
48. Kohlberger, P.; Loesch, A.; Koelbl, H.; Breitenecker, G.; Kainz, C.; Gitsch, G. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. Cancer Lett. 1996, 98, 151-155.
49. Khalifa, M. A.; Abdoh, A. A.; Mannel, R. S.; Haraway, S. D.; Walker, J. L.; Min, K. W. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer 1994, 73, 370-376.
50. Kim, J. W.; Kim, Y. T.; Kim, D. K.; Song, C. H.; Lee, J. W. Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol. Oncol. 1996, 60, 283-287.
51. Kristensen, G. B.; Holm, R.; Abeler, V. M.; Trope, C. G. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer 1996, 78, 433-440.
52. Kimmig, R.; Pfeiffer, D.; Landsmann, H.; Hepp, H. Quantitative determination of the epidermal growth factor receptor in cervical cancer and normal cervical epithelium by 2-color flow cytometry: evidence for down-regulation in cervical cancer. Int. J. Cancer 1997, 74, 365-373.
53. Kersemaekers, A. M.; Fleuren, G. J.; Kenter, G. G.; Van den Broek, L. J.; Uljee, S. M.; Hermans, J.; Van de Vijver, M. J. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin. Cancer Res. 1999, 5, 577-586.
54. Berchuck, A.; Rodriguez, G.; Kamel, A.; Soper, J. T.; Clarke-Pearson, D. L.; Bast, R. C., Jr. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet. Gynecol. 1990, 76, 381-387.
55. Rosty, C.; Couturier, J.; Vincent-Salomon, A.; Genin, P.; Freneaux, P.; Sigal-Zafrani, B.; Sastre-Garau, X. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. Int. J. Gynecol. Pathol. 2004, 23, 13-17.
56. El-Rayes, B. F.; LoRusso, P. M. Targeting the epidermal growth factor receptor. Br. J. Cancer 2004, 91, 418-424.
57. Sliwkowski, M. X.; Lofgren, J. A.; Lewis, G. D.; Hotaling, T. E.; Fendly, B. M.; Fox, J. A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 1999, 26, 60-70.
58. Izumi, Y.; Xu, L.; di Tomaso, E.; Fukumura, D.; Jain, R. K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416, 279-280.
59. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A.; et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
60. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344, 783-792.
61. Untch, M.; Eidtmann, H.; du Bois, A.; Meerpohl, H. G.; Thomssen, C.; Ebert, A.; Harbeck, N.; Jackisch, C.; Heilman, V.; Emons, G.; Wallwiener, D.; Wiese, W.; Blohmer, J. U.; Hoffken, K.; Kuhn, W.; Reichardt, P.; Muscholl, M.; Pauschinger, M.; Langer, B.; Luck, H. J. Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. Eur. J. Cancer 2004, 40, 988-997.
62. Burris, H., 3rd; Yardley, D.; Jones, S.; Houston, G.; Broome, C.; Thompson, D.; Greco, F. A.; White, M.; Hainsworth, J. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J. Clin. Oncol. 2004, 22, 1621-1629.
63. Cho, H. S.; Mason, K.; Ramyar, K. X.; Stanley, A. M.; Gabelli, S. B.; Denney, D. W., Jr.; Leahy, D. J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421, 756-760.
64. Agus, D. B.; Gordon, M. S.; Taylor, C.; Natale, R. B.; Karlan, B.; Mendelson, D. S.; Press, M. F.; Allison, D. E.; Sliwkowski, M. X.; Lieberman, G.; Kelsey, S. M.; Fyfe, G. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 2534-2543.
65. Baselga, J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eur. J. Cancer 2001, 37(Suppl 4), S16-22.
66. Saltz, L. B.; Meropol, N. J.; Loehrer, P. J., Sr.; Needle, M. N.; Kopit, J.; Mayer, R. J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 1201-1208.
67. Yang, X. D.; Jia, X. C.; Corvalan, J. R.; Wang, P.; Davis, C. G. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 2001, 38, 17-23.
68. Rowinsky, E. K.; Schwartz, G. H.; Gollob, J. A.; Thompson, J. A.; Vogelzang, N. J.; Figlin, R.; Bukowski, R.; Haas, N.; Lockbaum, P.; Li, Y. P.; Arends, R.; Foon, K. A.; Schwab, G.; Dutcher, J. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 2004, 22, 3003-3015.
69. Los, M.; Burek, C. J.; Stroh, C.; Benedyk, K.; Hug, H.; Mackiewicz, A. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov. Today 2003, 8, 67-77.
70. Paez, J. G.; Janne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
71. Leslie, K. K.; Laidler, L.; Albitar, L.; Davies, S.; Holmes, A.; Nguyen, T.; Bolnick, J.; Dai, D. Tyrosine kinase inhibitors in endometrial cancer. Int. J. Gynecol. Cancer 2005, 15, 409-411.
72. Calvo, E.; Tolcher, A. W.; Hammond, L. A.; Patnaik, A.; de Bono, J. S.; Eiseman, I. A.; Olson, S. C.; Lenehan, P. F.; McCreery, H.; Lorusso, P.; Rowinsky, E. K. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Clin. Cancer Res. 2004, 10, 7112-7120.
73. Rusnak, D. W.; Affleck, K.; Cockerill, S. G.; Stubberfield, C.; Harris, R.; Page, M.; Smith, K. J.; Guntrip, S. B.; Carter, M. C.; Shaw, R. J.; Jowett, A.; Stables, J.; Topley, P.; Wood, E. R.; Brignola, P. S.; Kadwell, S. H.; Reep, B. R.; Mullin, R. J.; Alligood, K. J.; Keith, B. R.; Crosby, R. M.; Murray, D. M.; Knight, W. B.; Gilmer, T. M.; Lackey, K. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001, 61, 7196-7203.
74. Rusnak, D. W.; Lackey, K.; Affleck, K.; Wood, E. R.; Alligood, K. J.; Rhodes, N.; Keith, B. R.; Murray, D. M.; Knight, W. B.; Mullin, R. J.; Gilmer, T. M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001, 1, 85-94.
75. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64, 6652-6659.
76. Druker, B. J. Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol. 2003, 40, 50-58.
77. O'Brien, S. G.; Guilhot, F.; Larson, R. A.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J. J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Lechner, K.; Nielsen, J. L.; Rousselot, P.; Reiffers, J.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J. M.; Kantarjian, H.; Taylor, K.; Verhoef, G.; Bolton, A. E.; Capdeville, R.; Druker, B. J. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2003, 348, 994-1004.
78. Goldman, J. M.; Melo, J. V. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N. Engl. J. Med. 2003, 349, 1451-1464.
79. Dagher, R.; Cohen, M.; Williams, G.; Rothmann, M.; Gobburu, J.; Robbie, G.; Rahman, A.; Chen, G.; Staten, A.; Griebel, D.; Pazdur, R. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin. Cancer Res. 2002, 8, 3034-3038.
80. Schmandt, R. E.; Broaddus, R.; Lu, K. H.; Shvartsman, H.; Thornton, A.; Malpica, A.; Sun, C.; Bodurka, D. C.; Gershenson, D. M. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003, 98, 758-764.
81. Slomovitz, B. M.; Broaddus, R. R.; Schmandt, R.; Wu, W.; Oh, J. C.; Ramondetta, L. M.; Burke, T. W.; Gershenson, D. M.; Lu, K. H. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol. Oncol. 2004, 95, 32-36.
82. Zhang, Y.; Yu, D.; Xia, W.; Hung, M. C. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene 1995, 10, 1947-1954.
83. Madhusudan, S.; Tamir, A.; Bates, N.; Flanagan, E.; Gore, M. E.; Barton, D. P.; Harper, P.; Seckl, M.; Thomas, H.; Lemoine, N. R.; Charnock, M.; Habib, N. A.; Lechler, R.; Nicholls, J.; Pignatelli, M.; Ganesan, T. S. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin. Cancer Res. 2004, 10, 2986-2996.
84. Xing, X.; Zhang, S.; Chang, J. Y.; Tucker, S. D.; Chen, H.; Huang, L.;Hung, M. C. Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. Gene Ther. 1998, 5, 1538-1544.
85. Hidalgo, M.; Rowinsky, E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000, 19, 6680-6686.
86. Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S. I.; Puc, J.; Miliaresis, C.; Rodgers, L.; McCombie, R.; Bigner, S. H.; Giovanella, B. C.; Ittmann, M.; Tycko, B.; Hibshoosh, H.; Wigler, M. H.; Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275, 1943-1947.
87. Tashiro, H.; Blazes, M. S.; Wu, R.; Cho, K. R.; Bose, S.; Wang, S. I.; Li, J.; Parsons, R.; Ellenson, L. H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997, 57, 3935-3940.
88. Minaguchi, T.; Yoshikawa, H.; Oda, K.; Ishino, T.; Yasugi, T.; Onda, T.; Nakagawa, S.; Matsumoto, K.; Kawana, K.; Taketani, Y. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin. Cancer Res. 2001, 7, 2636-2642.
89. Altomare, D. A.; Wang, H. Q.; Skele, K. L.; De Rienzo, A.; Klein-Szanto, A. J.; Godwin, A. K.; Testa, J. R. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23, 5853-5857.
90. Vignot, S.; Faivre, S.; Aguirre, D.; Raymond, E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005, 16, 525-537.
91. Podsypanina, K.; Lee, R. T.; Politis, C.; Hennessy, I.; Crane, A.; Puc, J.; Neshat, M.; Wang, H.; Yang, L.; Gibbons, J.; Frost, P.; Dreisbach, V.; Blenis, J.; Gaciong, Z.; Fisher, P.; Sawyers, C.; Hedrick-Ellenson, L.; Parsons, R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA 2001, 98, 10320-10325.
92. Raymond, E.; Alexandre, J.; Faivre, S.; Vera, K.; Materman, E.; Boni, J.; Leister, C.; Korth-Bradley, J.; Hanauske, A.; Armand, J. P. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 2004, 22, 2336-2347.
93. Atkins, M. B.; Hidalgo, M.; Stadler, W. M.; Logan, T. F.; Dutcher, J. P.; Hudes, G. R.; Park, Y.; Liou, S. H.; Marshall, B.; Boni, J. P.; Dukart, G.; Sherman, M. L. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 2004, 22, 909-918.
94. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389, 349-352.
95. Juan, L. J.; Shia, W. J.; Chen, M. H.; Yang, W. M.; Seto, E.; Lin, Y. S.; Wu, C. W. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 2000, 275, 20436-20443.
96. Wang, C.; Fu, M.; Angeletti, R. H.; Siconolfi-Baez, L.; Reutens, A. T.; Albanese, C.; Lisanti, M. P.; Katzenellenbogen, B. S.; Kato, S.; Hopp, T.; Fuqua, S. A.; Lopez, G. N.; Kushner, P. J.; Pestell, R. G. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. 2001, 276, 18375-18383.
97. Singal, R.; Wang, S. Z.; Sargent, T.; Zhu, S. Z.; Ginder, G. D. Methylation of promoter proximal-transcribed sequences of an embryonic globin gene inhibits transcription in primary erythroid cells and promotes formation of a cell type-specific methyl cytosine binding complex. J. Biol. Chem. 2002, 277, 1897-1905.
98. Prokhortchouk, E.; Hendrich, B. Methyl-CpG binding proteins and cancer: are MeCpGs more important than MBDs? Oncogene 2002, 21, 5394-5399.
99. Bender, C. M.; Zingg, J. M.; Jones, P. A. DNA methylation as a target for drug design. Pharm. Res. 1998, 15, 175-187.
100. Strathdee, G.; Appleton, K.; Illand, M.; Millan, D. W.; Sargent, J.; Paul, J.; Brown, R. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 2001, 158, 1121-1127.
101. Medina, V.; Edmonds, B.; Young, G. P.; James, R.; Appleton, S.; Zalewski, P. D. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 1997, 57, 3697-3707.
102. Richon, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA 1998, 95, 3003-3007.
103. Marks, P.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1, 194-202.
104. Melnick, A.; Licht, J. D. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr. Opin. Hematol. 2002, 9, 322-332.
105. Wang, R.; Brunner, T.; Zhang, L.; Shi, Y. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene 1998, 17, 1503-1508.
106. Rajgolikar, G.; Chan, K. K.; Wang, H. C. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res. Treat. 1998, 51, 29-38.
107. Sandor, V.; Senderowicz, A.; Mertins, S.; Sackett, D.; Sausville, E.; Blagosklonny, M. V.; Bates, S. E. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer 2000, 83, 817-825.
108. Ueda, H.; Nakajima, H.; Hori, Y.; Goto, T.; Okuhara, M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci. Biotechnol. Biochem. 1994, 58, 1579-1583.
109. Sandor, V.; Bakke, S.; Robey, R. W.; Kang, M. H.; Blagosklonny, M. V.; Bender, J.; Brooks, R.; Piekarz, R. L.; Tucker, E.; Figg, W. D.; Chan, K. K.; Goldspiel, B.; Fojo, A. T.; Balcerzak, S. P.; Bates, S. E. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 2002, 8, 718-728.
110. Marshall, J. L.; Rizvi, N.; Kauh, J.; Dahut, W.; Figuera, M.; Kang, M. H.; Figg, W. D.; Wainer, I.; Chaissang, C.; Li, M. Z.; Hawkins, M. J. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2002, 2, 325-332.
111. Byrd, J. C.; Marcucci, G.; Parthun, M. R.; Xiao, J. J.; Klisovic, R. B.; Moran, M.; Lin, T. S.; Liu, S.; Sklenar, A. R.; Davis, M. E.; Lucas, D. M.; Fischer, B.; Shank, R.; Tejaswi, S. L.; Binkley, P.; Wright, J.; Chan, K. K.; Grever, M. R. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105, 959-967.
112. Christman, J. K. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002, 21, 5483-5495.
113. Plumb, J. A.; Strathdee, G.; Sludden, J.; Kaye, S. B.; Brown, R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine- induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000, 60, 6039-6044.
114. Schwartsmann, G.; Schunemann, H.; Gorini, C. N.; Filho, A. F.; Garbino, C.; Sabini, G.; Muse, I.; DiLeone, L.; Mans, D. R. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest. New Drugs 2000, 18, 83-91.
115. Thibault, A.; Figg, W. D.; Bergan, R. C.; Lush, R. M.; Myers, C. E.; Tompkins, A.; Reed, E.; Samid, D. A phase II study of 5-aza- 2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori. 1998, 84, 87-89.
116. Yogelzang, N. J.; Herndon, J. E., 2nd; Cirrincione, C.; Harmon, D. C.; Antman, K. H.; Corson, J. M.; Suzuki, Y.; Citron, M. L.; Green, M. R. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 1997, 79, 2237-2242.
117. Wijermans, P.; Lubbert, M.; Verhoef, G.; Bosly, A.; Ravoet, C.; Andre, M.; Ferrant, A. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 2000, 18, 956-962.
118. Issa, J. P.; Garcia-Manero, G.; Giles, F. J.; Mannari, R.; Thomas, D.; Faderl, S.; Bayar, E.; Lyons, J.; Rosenfeld, C. S.; Cortes, J.; Kantarjian, H. M. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103, 1635-1640.
119. Pohlmann, P.; DiLeone, L. P.; Cancella, A. I.; Caldas, A. P.; Dal Lago, L.; Campos, O., Jr.; Monego, E.; Rivoire, W.; Schwartsmann, G. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am. J. Clin. Oncol. 2002, 25, 496-501.
120. Agarwal, R.; Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003, 3, 502-516.
121. Frankel, A.; Mills, G. B. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin. Cancer Res. 1996, 2, 1307-1313.
122. Satyam, A.; Hocker, M. D.; Kane-Maguire, K. A.; Morgan, A. S.; Villar, H. O.; Lyttle, M. H. Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase. J. Med. Chem. 1996, 39, 1736-1747.
123. Izbicka, E.; Lawrence, R.; Cerna, C.; Von Hoff, D. D.;Sanderson, P. E. Activity of TER286 against human tumor colony-forming units. Anticancer Drugs 1997, 8, 345-348.
124. Davis, R. J. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103, 239-252.
125. Hagemann, C.; Blank, J. L. The ups and downs of MEK kinase interactions. Cell Signal. 2001, 13, 863-875.
126. Rosen, L. S.; Laxa, B.; Boulos, L.; Wiggins, L.; Keck, J. G.; Jameson, A. J.; Parra, R.; Patel, K.; Brown, G. L. Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies. Clin. Cancer Res. 2004, 10, 3689-3698.
127. Kavanagh, J. J.; Gershenson, D. M.; Choi, H.; Lewis, L.; Patel, K.; Brown, G. L.; Garcia, A.; Spriggs, D. R. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int. J. Gynecol. Cancer 2005, 15, 593-600.
128. Arts, H. J.; Katsaros, D.; de Vries, E. G.; Massobrio, M.; Genta, F.; Danese, S.; Arisio, R.; Scheper, R. J.; Kool, M.; Scheffer, G. L.; Willemse, P. H.; van der Zee, A. G.; Suurmeijer, A. J. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin. Cancer Res. 1999, 5, 2798-2805.
129. Schneider, J.; Rubio, M. P.; Barbazan, M. J.; Rodriguez-Escudero, F. J.; Seizinger, B. R.; Castresana, J. S. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J. Natl. Cancer Inst. 1994, 86, 850-855.
130. Baekelandt, M. M.; Holm, R.; Nesland, J. M.; Trope, C. G.; Kristensen, G. B. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res. 2000, 20, 1061-1067.
131. Adams, J. Proteasome inhibition in cancer: development of PS-341. Semin. Oncol. 2001, 28, 613-619.
132. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Chauhan, D.; Fanourakis, G.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T. A.; Treon, S. P.; Munshi, N. C.; Richardson, P. G.; Hideshima, T.; Anderson, K. C. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA 2002, 99, 14374-14379.
133. Scheffner, M.; Whitaker, N. J. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol. 2003, 13, 59-67.
134. Workman, P. Overview: translating Hsp90 biology into Hsp90 drugs. Curr. Cancer Drug Targets 2003, 3, 297-300.
135. Luo, L. Y.; Herrera, I.; Soosaipillai, A.; Diamandis, E. P. Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. Br. J. Cancer 2002, 87, 339-343.
136. Wataba, K.; Saito, T.; Fukunaka, K.; Ashihara, K.; Nishimura, M.; Kudo, R. Over-expression of heat shock proteins in carcinogenic endometrium. Int. J. Cancer 2001, 91, 448-456.
137. Papandreou, C. N.; Daliani, D. D.; Nix, D.; Yang, H.; Madden, T.; Wang, X.; Pien, C. S.; Millikan, R. E.; Tu, S. M.; Pagliaro, L.; Kim, J.; Adams, J.; Elliott, P.; Esseltine, D.; Petrusich, A.; Dieringer, P.; Perez, C.; Logothetis, C. J. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 2004, 22, 2108-2121.
138. Barlogie, B.; Shaughnessy, J.; Zangari, M.; Tricot, G. High-dose therapy and immunomodulatory drugs in multiple myeloma. Semin Oncol. 2002, 29, 26-33.
139. Owa, T.; Yoshino, H.; Yoshimatsu, K.; Nagasu, T. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr. Med. Chem. 2001, 8, 1487-1503.
140. Richardson, P. G.; Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S. V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R. Z.; Kuter, D.; Limentani, S. A.; Lee, S.; Hideshima, T.; Esseltine, D. L.; Kauffman, M.; Adams, J.; Schenkein, D. P.; Anderson, K. C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348, 2609-2617.
141. Davis, N. B.; Taber, D. A.; Ansari, R. H.; Ryan, C. W.; George, C.; Vokes, E. E.; Vogelzang, N. J.; Stadler, W. M. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J. Clin. Oncol. 2004, 22, 115-119.
142. Supko, J. G.; Hickman, R. L.; Grever, M. R.; Malspeis, L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 1995, 36, 305-315.
143. Neckers, L. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr. Med. Chem. 2003, 10, 733-739.
144. Goetz, M. P.; Toft, D.; Reid, J.; Ames, M.; Stensgard, B.; Safgren, S.; Adjei, A. A.; Sloan, J.; Atherton, P.; Vasile, V.; Salazaar, S.; Adjei, A.; Croghan, G.; Erlichman, C. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J. Clin. Oncol. 2005, 23, 1078-1087.
145. Shapiro, G. I.; Harper, J. W. Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest. 1999, 104, 1645-1653.
146. Carmena, M.; Earnshaw, W. C. The cellular geography of aurora kinases. Nat. Rev. Mol. Cell Biol. 2003, 4, 842-854.
147. Harrington, E. A.; Bebbington, D.; Moore, J.; Rasmussen, R. K.; Ajose-Adeogun, A. O.; Nakayama, T.; Graham, J. A.; Demur, C.; Hercend, T.; Diu-Hercend, A.; Su, M.; Golec, J. M.; Miller, K. M. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 2004, 10, 262-267.
148. Hu, W.; Kavanagh, J. J.; Deaver, M.; Johnston, D. A.; Freedman, R. S.; Verschraegen, C. F.; Sen, S. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol. Res. 2005, 15, 49-57.
149. Ditchfield, C.; Johnson, V. L.; Tighe, A.; Ellston, R.; Haworth, C.; Johnson, T.; Mortlock, A.; Keen, N.; Taylor, S. S. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 2003, 161, 267-280.
150. Margolis, R. L.; Lohez, O. D.; Andreassen, P. R. G1 tetraploidy checkpoint and the suppression of tumorigenesis. J. Cell Biochem. 2003, 88, 673-683.
151. Katayama, H.; Sasai, K.; Kawai, H.; Yuan, Z. M.; Bondaruk, J.; Suzuki, F.; Fujii, S.; Arlinghaus, R. B.; Czerniak, B. A.; Sen, S. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat. Genet. 2004, 36, 55-62.
152. Sedlacek, H. H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol. 2001, 38, 139-170.
153. Shapiro, G. I. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin. Cancer Res. 2004, 10, 4270s-4275s.
154. Liu, G.; Gandara, D. R.; Lara, P. N., Jr.; Raghavan, D.; Doroshow, J. H.; Twardowski, P.; Kantoff, P.; Oh, W.; Kim, K.; Wilding, G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgenin-dependent prostate cancer. Clin. Cancer Res. 2004, 10, 924-928.
155. Raju, U.; Nakata, E.; Mason, K. A.; Ang, K. K.; Milas, L. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res. 2003, 63, 3263-3267.
156. Smith, C. L. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod. 1998, 58, 627-632.
157. Kato, S.; Endoh, H.; Masuhiro, Y.; Kitamoto, T.; Uchiyama, S.; Sasaki, H.; Masushige, S.; Gotoh, Y.; Nishida, E.; Kawashima, H.; Metzger, D.; Chambon, P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270, 1491-1494.
158. Campbell, R. A.; Bhat-Nakshatri, P.; Patel, N. M.; Constantinidou, D.; Ali, S.; Nakshatri, H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 2001, 276, 9817-9824.
159. Bunone, G.; Briand, P. A.; Miksicek, R. J.; Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15, 2174-2183.
160. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351, 1451-1467.
161. Perez-Gracia, J. L.; Carrasco, E. M. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol. Oncol. 2002, 84, 201-209.
162. Rao, B. R.; Slotman, B. J. Endocrine factors in common epithelial ovarian cancer. Endocr. Rev. 1991, 12, 14-26.
163. Hatch, K. D.; Beecham, J. B.; Blessing, J. A.; Creasman, W. T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991, 68, 269-271.
164. Sasano, H.; Harada, N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr. Rev. 1998, 19, 593-607.
165. Thijssen, J. H.; Daroszewski, J.; Milewicz, A.; Blankenstein, M. A. Local aromatase activity in human breast tissues. J. Steroid Biochem. Mol. Biol. 1993, 44, 577-582.
166. Miller, W. R.; Anderson, T. J.; Dixon, J. M. Anti-tumor effects of letrozole. Cancer Invest. 2002, 20(Suppl 2), 15-21.
167. Watanabe, K.; Sasano, H.; Harada, N.; Ozaki, M.; Niikura, H.; Sato, S.; Yajima, A. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am. J. Pathol. 1995, 146, 491-500.
168. Baum, M.; Budzar, A. U.; Cuzick, J.; Forbes, J.; Houghton, J. H.; Klijn, J. G.; Sahmoud, T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359, 2131-2139.
169. Baum, M.; Buzdar, A.; Cuzick, J.; Forbes, J.; Houghton, J.; Howell, A.; Sahmoud, T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003, 98, 1802-1810.
170. del Carmen, M. G.; Fuller, A. F.; Matulonis, U.; Horick, N. K.; Goodman, A.; Duska, L. R.; Penson, R.; Campos, S.; Roche, M.;Seiden, M. V. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol. Oncol. 2003, 91, 596-602.
171. Goss, P. E.; Ingle, J. N.; Martino, S.; Robert, N. J.; Muss, H. B.; Piccart, M. J.; Castiglione, M.; Tu, D.; Shepherd, L. E.; Pritchard, K. I.; Livingston, R. B.; Davidson, N. E.; Norton, L.; Perez, E. A.; Abrams, J. S.; Therasse, P.; Palmer, M. J.; Pater, J. L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 2003, 349, 1793-1802.
172. Bowman, A.; Gabra, H.; Langdon, S. P.; Lessells, A.; Stewart, M.; Young, A.; Smyth, J. F. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin. Cancer Res. 2002, 8, 2233-2239.
173. Papadimitriou, C. A.; Markaki, S.; Siapkaras, J.; Vlachos, G.; Efstathiou, E.; Grimani, I.; Hamilos, G.; Zorzou, M.; Dimopoulos, M. A. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004, 66, 112-117.
174. di Salle, E.; Ornati, G.; Giudici, D.; Lassus, M.; Evans, T. R.;Coombes, R. C. Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 1992, 43, 137-143.
175. Brodie, A. M.; Garrett, W. M.; Hendrickson, J. R.; Tsai-Morris, C. H.; Marcotte, P. A.; Robinson, C. H. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids 1981, 38, 693-702.
176. Coombes, R. C.; Hall, E.; Gibson, L. J.; Paridaens, R.; Jassem, J.; Delozier, T.; Jones, S. E.; Alvarez, I.; Bertelli, G.; Ortmann, O.; Coates, A. S.; Bajetta, E.; Dodwell, D.; Coleman, R. E.; Fallowfield, L. J.; Mickiewicz, E.; Andersen, J.; Lonning, P. E.; Cocconi, G.; Stewart, A.; Stuart, N.; Snowdon, C. F.; Carpentieri, M.; Massimini, G.; Bliss, J. M. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 2004, 350, 1081-1092.
177. Addo, S.; Yates, R. A.; Laight, A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br. J. Cancer 2002, 87, 1354-1359.
178. Howell, A.; DeFriend, D. J.; Robertson, J. F.; Blamey, R. W.; Anderson, L.; Anderson, E.; Sutcliffe, F. A.; Walton, P. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br. J. Cancer 1996, 74, 300-308.
179. Osborne, C. K.; Pippen, J.; Jones, S. E.; Parker, L. M.; Ellis, M.; Come, S.; Gertler, S. Z.; May, J. T.; Burton, G.; Dimery, I.; Webster, A.; Morris, C.; Elledge, R.; Buzdar, A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 2002, 20, 3386-3395.
180. Howell, A.; Robertson, J. F.; Quaresma Albano, J.; Aschermannova, A.; Mauriac, L.; Kleeberg, U. R.; Vergote, I.; Erikstein, B.; Webster, A.; Morris, C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 2002, 20, 3396-3403.
181. Thigpen, J. T.; Blessing, J. A.; DiSaia, P. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: results of therapy and correlation with estrogen and progesterone receptor levels-the Gynecologic Oncology Group experience. In Endocrinology and Malignancy; Baulier, E.; Iacobelli, S.; McGuire, W.; Eds.; New York: Parthenon Publishers. 1986, 446-454.
182. Thigpen, J. T.; Brady, M. F.; Alvarez, R. D.; Adelson, M. D.; Homesley, H. D.; Manetta, A.; Soper, J. T.; Given, F. T. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J. Clin. Oncol. 1999, 17, 1736-1744.
183. Siemeister, G.; Martiny-Baron, G.; Marme, D. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metastas. Rev. 1998, 17, 241-248.
184. Hicklin, D. J.; Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23, 1011-1027.
185. Gadducci, A.; Viacava, P.; Cosio, S.; Cecchetti, D.; Fanelli, G.; Fanucchi, A.; Teti, G.; Genazzani, A. R. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res. 2003, 23, 3001-3008.
186. Yamamoto, S.; Konishi, I.; Mandai, M.; Kuroda, H.; Komatsu, T.; Nanbu, K.; Sakahara, H.; Mori, T. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br. J. Cancer 1997, 76, 1221-1227.
187. Eisen, T. Thalidomide in solid malignancies. J. Clin. Oncol. 2002, 20, 2607-2609.
188. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Chauhan, D.; Richardson, P. G.; Hideshima, T.; Munshi, N. C.; Treon, S. P.; Anderson, K. C. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99, 4525-4530.
189. Marriott, J. B.; Clarke, I. A.; Czajka, A.; Dredge, K.; Childs, K.; Man, H. W.; Schafer, P.; Govinda, S.; Muller, G. W.; Stirling, D. I.; Dalgleish, A. G. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. Cancer Res. 2003, 63, 593-599.
190. Richardson, P. G.; Schlossman, R. L.; Weller, E.; Hideshima, T.; Mitsiades, C.; Davies, F.; LeBlanc, R.; Catley, L. P.; Doss, D.; Kelly, K.; McKenney, M.; Mechlowicz, J.; Freeman, A.; Deocampo, R.; Rich, R.; Ryoo, J. J.; Chauhan, D.; Balinski, K.; Zeldis, J.; Anderson, K. C. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100, 3063-3067.
191. Bartlett, J. B.; Michael, A.; Clarke, I. A.; Dredge, K.; Nicholson, S.; Kristeleit, H.; Polychronis, A.; Pandha, H.; Muller, G. W.; Stirling, D. I.; Zeldis, J.; Dalgleish, A. G. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br. J. Cancer 2004, 90, 955-961.
192. Abramson, N.; Stokes, P. K.; Luke, M.; Marks, A. R.; Harris, J. M. Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide. J. Clin. Oncol. 2002, 20, 1147-1149.
193. Kim, K. J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362, 841-844.
194. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335-2342.
195. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307, 58-62.
196. Bevacizumab combined with chemotherapy improves progression-free survival for patients with advanced breast cancer. http://www.cancer.gov 2005.
197. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K. H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60, 2178-2189.
198. Bast, R. C., Jr.; Klug, T. L.; St John, E.; Jenison, E.; Niloff, J. M.; Lazarus, H.; Berkowitz, R. S.; Leavitt, T.; Griffiths, C. T.; Parker, L.; Zurawski, V. R., Jr.; Knapp, R. C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 1983, 309, 883-887.
199. Schlienger, K.; Chu, C. S.; Woo, E. Y.; Rivers, P. M.; Toll, A. J.; Hudson, B.; Maus, M. V.; Riley, J. L.; Choi, Y.; Coukos, G.; Kaiser, L. R.; Rubin, S. C.; Levine, B. L.; Carroll, R. G.; June, C. H. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin. Cancer Res. 2003, 9, 1517-1527.
200. Schuler, G.; Schuler-Thurner, B.; Steinman, R. M. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 2003, 15, 138-147.
201. Bedell, M. A.; Jones, K. H.; Laimins, L. A. The E6-E7 region of human papillomavirus type 18 is sufficient for transformation of NIH 3T3 and rat-1 cells. J. Virol. 1987, 61, 3635-3640.
202. Wideroff, L.; Schiffman, M. H.; Nonnenmacher, B.; Hubbert, N.; Kirnbauer, R.; Greer, C. E.; Lowy, D.; Lorincz, A. T.; Manos, M. M.; Glass, A. G.; et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J. Infect. Dis. 1995, 172, 1425-1430.
203. Christensen, N. D.; Kirnbauer, R.; Schiller, J. T.; Ghim, S. J.; Schlegel, R.; Jenson, A. B.; Kreider, J. W. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 1994, 205, 329-335.
204. Galloway, D. A. Papillomavirus vaccines in clinical trials. Lancet Infect. Dis. 2003, 3, 469-475.
205. Koutsky, L. A.; Ault, K. A.; Wheeler, C. M.; Brown, D. R.; Barr, E.; Alvarez, F. B.; Chiacchierini, L. M.; Jansen, K. U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 2002, 347, 1645-1651.
206. Harper, D. M.; Franco, E. L.; Wheeler, C.; Ferris, D. G.; Jenkins, D.; Schuind, A.; Zahaf, T.; Innis, B.; Naud, P.; De Carvalho, N. S.; Roteli-Martins, C. M.; Teixeira, J.; Blatter, M. M.; Korn, A. P.; Quint, W.; Dubin, G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364, 1757-1765.
207. Berg, M.; Difatta, J.; Hoiczyk, E.; Schlegel, R.; Ketner, G. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit. Proc. Natl. Acad. Sci. USA 2005, 102, 4590-4595.
208. Schultes, B. C.; Baum, R. P.; Niesen, A.; Noujaim, A. A.; Madiyalakan, R. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol. Immunother. 1998, 46, 201-212.
209. Nicodemus, C. F.; Schultes, B. C.; Hamilton, B. L. Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies. Exp. Rev. Vaccines 2002, 1, 35-48.
210. Mobus, V. J.; Baum, R. P.; Bolle, M.; Kreienberg, R.; Noujaim, A. A.; Schultes, B. C.; Nicodemus, C. F. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am. J. Obstet. Gynecol. 2003, 189, 28-36.
211. Berek, J. S.; Taylor, P. T.; Gordon, A.; Cunningham, M. J.; Finkler, N.; Orr, J., Jr.; Rivkin, S.; Schultes, B. C.; Whiteside, T. L.; Nicodemus, C. F. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol. 2004, 22, 3507-3516.
212. Chu, N. R.; Wu, H. B.; Wu, T.; Boux, L. J.; Siegel, M. I.; Mizzen, L. A. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. 2000, 121, 216-225.
213. Goldstone, S. E.; Palefsky, J. M.; Winnett, M. T.; Neefe, J. R. Activity of HspE7, a Novel Immunotherapy, in Patients with Anogenital Warts. Dis. Colon Rectum 2001, 45, 502-507.
214. Shih, C.; Chen, V. J.; Gossett, L. S.; Gates, S. B.; MacKellar, W. C.; Habeck, L. L.; Shackelford, K. A.; Mendelsohn, L. G.; Soose, D. J.; Patel, V. F.; Andis, S. L.; Bewley, J. R.; Rayl, E. A.; Moroson, B. A.; Beardsley, G. P.; Kohler, W.; Ratnam, M.; Schultz, R. M. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997, 57, 1116-1123.
215. Niyikiza, C.; Baker, S. D.; Seitz, D. E.; Walling, J. M.; Nelson, K.; Rusthoven, J. J.; Stabler, S. P.; Paoletti, P.; Calvert, A. H.; Allen, R. H. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. 2002, 1, 545-552.
216. Clarke, S. J.; Abratt, R.; Goedhals, L.; Boyer, M. J.; Millward, M. J.;Ackland, S. P. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann. Oncol. 2002, 13, 737-741.
217. Rusthoven, J. J.; Eisenhauer, E.; Butts, C.; Gregg, R.; Dancey, J.; Fisher, B.; Iglesias, J. Multitargeted antifolate LY231514 as firstline chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 1999, 17, 1194.
218. Adjei, A. A.; Erlichman, C.; Sloan, J. A.; Reid, J. M.; Pitot, H. C.; Goldberg, R. M.; Peethambaram, P.; Atherton, P.; Hanson, L. J.; Alberts, S. R.;Jett, J. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J. Clin. Oncol. 2000, 18, 1748-1757.
219. Goedhals, L.; van Wijk, A. L. MTA (LY231514) in advanced carinoma of the cervix. Ann. Oncol. 1998, 9(Suppl 2), 339a.
220. Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995, 55, 2325-2333.
221. Lee, F. Y.; Borzilleri, R.; Fairchild, C. R.; Kim, S. H.; Long, B. H.; Reventos-Suarez, C.; Vite, G. D.; Rose, W. C.; Kramer, R. A. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 2001, 7, 1429-1437.
222. Eng, C.; Kindler, H. L.; Nattam, S.; Ansari, R. H.; Kasza, K.; Wade-Oliver, K.; Vokes, E. E. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann. Oncol. 2004, 15, 928-932.
223. Wagner, M. M.; Paul, D. C.; Shih, C.; Jordan, M. A.; Wilson, L.; Williams, D. C. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother. Pharmacol. 1999, 43, 115-125.
224. Stevenson, J. P.; Sun, W.; Gallagher, M.; Johnson, R.; Vaughn, D.; Schuchter, L.; Algazy, K.; Hahn, S.; Enas, N.; Ellis, D.; Thornton, D.;O'Dwyer, P. J. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Clin. Cancer Res. 2002, 8, 2524-2529.
225. Edelman, M. J.; Gandara, D. R.; Hausner, P.; Israel, V.; Thornton, D.; DeSanto, J.; Doyle, L. A. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2003, 39, 197-199.
226. Johnston, S. R. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin. Cancer Res. 2005, 11, 889s-899s.